Role and relevance of Trkb mutations and expression in non-small cell lung cancer

Taishi Harada, Yasushi Yatabe, Masafumi Takeshita, Takaomi Koga, Tokujiro Yano, Yisong Wang, Giuseppe Giaccone

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Purpose: TrkB has been involved in poor cancer outcome. TrkB mutations have been reported in non-small cell lung cancer. In this study, we aimed at characterizing the role of three potentially sensitizing TrkB mutations previously reported in lung cancer. Experimental Design: We characterized three activation loop mutants of TrkB (M713I, R715G, and R734C) in terms of pathway activation/phosphorylation, migration, anchorage-independent growth, and sensitivity to a Trk inhibitor, using NIH3T3 cells and Baf3 cells. We also sequenced the tyrosine kinase domain of TrkB in a large number of lung cancer samples of East-Asian origin and cell lines. Results: None of the mutants were constitutively active in NIH3T3 transformation and migration assays. M713I and R734C mutants showed low levels of autophosphorylation in comparison with wild-type TrkB. Although R715G showed similar level of autophosphorylation to wild-type TrkB on brain-derived neurotrophic factor stimulation, the mutant was not as competent as wild-type TrkB in supporting interleukin-3-independent growth of Baf3 cells. In addition, the Trk inhibitor AZD6918 inhibited wild-type TrkB-induced cell migration and cell growth, whereas the mutants were relatively resistant to the Trk inhibitor compared with wild-type TrkB. We could not confirm the presence of nonsynonymous mutation in 78 lung cancer samples and 29 cell lines. Conclusions: Wild-type, but not mutant, TrkB enhances cell migration and transformation. Our study suggests that TrkB mutations should not be used for selection of patients with lung cancer treated with Trk inhibitors. High expression of wild-type TrkB might be beneficial for studies of Trk inhibitors.

Original languageEnglish
Pages (from-to)2638-2645
Number of pages8
JournalClinical Cancer Research
Volume17
Issue number9
DOIs
Publication statusPublished - May 1 2011

Fingerprint

Non-Small Cell Lung Carcinoma
Lung Neoplasms
Mutation
Cell Movement
Growth
Cell Line
Interleukin-3
Brain-Derived Neurotrophic Factor
Protein-Tyrosine Kinases
Patient Selection
Research Design
Phosphorylation
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Harada, T., Yatabe, Y., Takeshita, M., Koga, T., Yano, T., Wang, Y., & Giaccone, G. (2011). Role and relevance of Trkb mutations and expression in non-small cell lung cancer. Clinical Cancer Research, 17(9), 2638-2645. https://doi.org/10.1158/1078-0432.CCR-10-3034

Role and relevance of Trkb mutations and expression in non-small cell lung cancer. / Harada, Taishi; Yatabe, Yasushi; Takeshita, Masafumi; Koga, Takaomi; Yano, Tokujiro; Wang, Yisong; Giaccone, Giuseppe.

In: Clinical Cancer Research, Vol. 17, No. 9, 01.05.2011, p. 2638-2645.

Research output: Contribution to journalArticle

Harada, T, Yatabe, Y, Takeshita, M, Koga, T, Yano, T, Wang, Y & Giaccone, G 2011, 'Role and relevance of Trkb mutations and expression in non-small cell lung cancer', Clinical Cancer Research, vol. 17, no. 9, pp. 2638-2645. https://doi.org/10.1158/1078-0432.CCR-10-3034
Harada, Taishi ; Yatabe, Yasushi ; Takeshita, Masafumi ; Koga, Takaomi ; Yano, Tokujiro ; Wang, Yisong ; Giaccone, Giuseppe. / Role and relevance of Trkb mutations and expression in non-small cell lung cancer. In: Clinical Cancer Research. 2011 ; Vol. 17, No. 9. pp. 2638-2645.
@article{1449d3ecea834fdd8ad7b65d836607ee,
title = "Role and relevance of Trkb mutations and expression in non-small cell lung cancer",
abstract = "Purpose: TrkB has been involved in poor cancer outcome. TrkB mutations have been reported in non-small cell lung cancer. In this study, we aimed at characterizing the role of three potentially sensitizing TrkB mutations previously reported in lung cancer. Experimental Design: We characterized three activation loop mutants of TrkB (M713I, R715G, and R734C) in terms of pathway activation/phosphorylation, migration, anchorage-independent growth, and sensitivity to a Trk inhibitor, using NIH3T3 cells and Baf3 cells. We also sequenced the tyrosine kinase domain of TrkB in a large number of lung cancer samples of East-Asian origin and cell lines. Results: None of the mutants were constitutively active in NIH3T3 transformation and migration assays. M713I and R734C mutants showed low levels of autophosphorylation in comparison with wild-type TrkB. Although R715G showed similar level of autophosphorylation to wild-type TrkB on brain-derived neurotrophic factor stimulation, the mutant was not as competent as wild-type TrkB in supporting interleukin-3-independent growth of Baf3 cells. In addition, the Trk inhibitor AZD6918 inhibited wild-type TrkB-induced cell migration and cell growth, whereas the mutants were relatively resistant to the Trk inhibitor compared with wild-type TrkB. We could not confirm the presence of nonsynonymous mutation in 78 lung cancer samples and 29 cell lines. Conclusions: Wild-type, but not mutant, TrkB enhances cell migration and transformation. Our study suggests that TrkB mutations should not be used for selection of patients with lung cancer treated with Trk inhibitors. High expression of wild-type TrkB might be beneficial for studies of Trk inhibitors.",
author = "Taishi Harada and Yasushi Yatabe and Masafumi Takeshita and Takaomi Koga and Tokujiro Yano and Yisong Wang and Giuseppe Giaccone",
year = "2011",
month = "5",
day = "1",
doi = "10.1158/1078-0432.CCR-10-3034",
language = "English",
volume = "17",
pages = "2638--2645",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Role and relevance of Trkb mutations and expression in non-small cell lung cancer

AU - Harada, Taishi

AU - Yatabe, Yasushi

AU - Takeshita, Masafumi

AU - Koga, Takaomi

AU - Yano, Tokujiro

AU - Wang, Yisong

AU - Giaccone, Giuseppe

PY - 2011/5/1

Y1 - 2011/5/1

N2 - Purpose: TrkB has been involved in poor cancer outcome. TrkB mutations have been reported in non-small cell lung cancer. In this study, we aimed at characterizing the role of three potentially sensitizing TrkB mutations previously reported in lung cancer. Experimental Design: We characterized three activation loop mutants of TrkB (M713I, R715G, and R734C) in terms of pathway activation/phosphorylation, migration, anchorage-independent growth, and sensitivity to a Trk inhibitor, using NIH3T3 cells and Baf3 cells. We also sequenced the tyrosine kinase domain of TrkB in a large number of lung cancer samples of East-Asian origin and cell lines. Results: None of the mutants were constitutively active in NIH3T3 transformation and migration assays. M713I and R734C mutants showed low levels of autophosphorylation in comparison with wild-type TrkB. Although R715G showed similar level of autophosphorylation to wild-type TrkB on brain-derived neurotrophic factor stimulation, the mutant was not as competent as wild-type TrkB in supporting interleukin-3-independent growth of Baf3 cells. In addition, the Trk inhibitor AZD6918 inhibited wild-type TrkB-induced cell migration and cell growth, whereas the mutants were relatively resistant to the Trk inhibitor compared with wild-type TrkB. We could not confirm the presence of nonsynonymous mutation in 78 lung cancer samples and 29 cell lines. Conclusions: Wild-type, but not mutant, TrkB enhances cell migration and transformation. Our study suggests that TrkB mutations should not be used for selection of patients with lung cancer treated with Trk inhibitors. High expression of wild-type TrkB might be beneficial for studies of Trk inhibitors.

AB - Purpose: TrkB has been involved in poor cancer outcome. TrkB mutations have been reported in non-small cell lung cancer. In this study, we aimed at characterizing the role of three potentially sensitizing TrkB mutations previously reported in lung cancer. Experimental Design: We characterized three activation loop mutants of TrkB (M713I, R715G, and R734C) in terms of pathway activation/phosphorylation, migration, anchorage-independent growth, and sensitivity to a Trk inhibitor, using NIH3T3 cells and Baf3 cells. We also sequenced the tyrosine kinase domain of TrkB in a large number of lung cancer samples of East-Asian origin and cell lines. Results: None of the mutants were constitutively active in NIH3T3 transformation and migration assays. M713I and R734C mutants showed low levels of autophosphorylation in comparison with wild-type TrkB. Although R715G showed similar level of autophosphorylation to wild-type TrkB on brain-derived neurotrophic factor stimulation, the mutant was not as competent as wild-type TrkB in supporting interleukin-3-independent growth of Baf3 cells. In addition, the Trk inhibitor AZD6918 inhibited wild-type TrkB-induced cell migration and cell growth, whereas the mutants were relatively resistant to the Trk inhibitor compared with wild-type TrkB. We could not confirm the presence of nonsynonymous mutation in 78 lung cancer samples and 29 cell lines. Conclusions: Wild-type, but not mutant, TrkB enhances cell migration and transformation. Our study suggests that TrkB mutations should not be used for selection of patients with lung cancer treated with Trk inhibitors. High expression of wild-type TrkB might be beneficial for studies of Trk inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=79955509427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955509427&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-10-3034

DO - 10.1158/1078-0432.CCR-10-3034

M3 - Article

C2 - 21242122

AN - SCOPUS:79955509427

VL - 17

SP - 2638

EP - 2645

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 9

ER -